Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study - Free with registration until Dec 15, 2025

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00594-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmoasia25&_hsenc=p2ANqtz--MTBKKdvFf3ZknaGB4dQVq15s9OOUU67mDGfdYY0gVfroaDwaGRz2kukwtELMHCsEj9rMygLEmbB_QmuEVH10CZ5r_xg&_hsmi=393141358&utm_content=393141358&utm_source=hs_email